Eribulin in the treatment of advanced breast cancer: real-world scenario from 39 Italian centers - ESEMPiO study

ESEMPiO Study Group

doi:10.2217/fon-2018-0324

Eribulin in the treatment of advanced breast cancer: real-world scenario from 39 Italian centers - ESEMPiO study

ESEMPiO Study Group

Research output: Contribution to journal › Article › peer-review

Abstract

AIM: We performed a multicenter retrospective cohort study of eribulin mesylate (EM) use in Italy, to describe the current practice for metastatic breast cancer patients (ESEMPiO) in the real-world.

PATIENTS & METHODS: Baseline characteristics, treatment administration and safety were summarized using descriptive statistics.

RESULTS: No safety concerns were raised in the population enrolled in the ESEMPiO database and treated in a real-life practice. Median progression-free survival and overall survival were 3.2 and 10.1 months, respectively. EM activity was similar between breast cancer subtypes.

CONCLUSION: In metastatic breast cancer patients treated with EM in 'real-world' setting, the clinician-registered outcomes were comparable to those reported in pivotal trials. Furthermore, EM maintained clinical activity and a tolerable safety profile.

Original language	English
Journal	Future Oncology
DOIs	https://doi.org/10.2217/fon-2018-0324
Publication status	E-pub ahead of print - Nov 9 2018

Access to Document

10.2217/fon-2018-0324

Fingerprint Dive into the research topics of 'Eribulin in the treatment of advanced breast cancer: real-world scenario from 39 Italian centers - ESEMPiO study'. Together they form a unique fingerprint.

Cite this

@article{04811c5ab6f44c2abbd95bd309f73e70,

title = "Eribulin in the treatment of advanced breast cancer: real-world scenario from 39 Italian centers - ESEMPiO study",

abstract = "AIM: We performed a multicenter retrospective cohort study of eribulin mesylate (EM) use in Italy, to describe the current practice for metastatic breast cancer patients (ESEMPiO) in the real-world.PATIENTS & METHODS: Baseline characteristics, treatment administration and safety were summarized using descriptive statistics.RESULTS: No safety concerns were raised in the population enrolled in the ESEMPiO database and treated in a real-life practice. Median progression-free survival and overall survival were 3.2 and 10.1 months, respectively. EM activity was similar between breast cancer subtypes.CONCLUSION: In metastatic breast cancer patients treated with EM in 'real-world' setting, the clinician-registered outcomes were comparable to those reported in pivotal trials. Furthermore, EM maintained clinical activity and a tolerable safety profile.",

author = "{ESEMPiO Study Group} and Sandro Barni and Luca Livraghi and Maria Morritti and Patrizia Vici and Andrea Michelotti and Saverio Cinieri and Caterina Fontanella and Luca Porcu and {Del Mastro}, Lucia and Fabio Puglisi",

year = "2018",

month = nov,

day = "9",

doi = "10.2217/fon-2018-0324",

language = "English",

journal = "Future Oncology",

issn = "1479-6694",

publisher = "Future Medicine Ltd.",

}

TY - JOUR

T1 - Eribulin in the treatment of advanced breast cancer

T2 - real-world scenario from 39 Italian centers - ESEMPiO study

AU - ESEMPiO Study Group

AU - Barni, Sandro

AU - Livraghi, Luca

AU - Morritti, Maria

AU - Vici, Patrizia

AU - Michelotti, Andrea

AU - Cinieri, Saverio

AU - Fontanella, Caterina

AU - Porcu, Luca

AU - Del Mastro, Lucia

AU - Puglisi, Fabio

PY - 2018/11/9

Y1 - 2018/11/9

N2 - AIM: We performed a multicenter retrospective cohort study of eribulin mesylate (EM) use in Italy, to describe the current practice for metastatic breast cancer patients (ESEMPiO) in the real-world.PATIENTS & METHODS: Baseline characteristics, treatment administration and safety were summarized using descriptive statistics.RESULTS: No safety concerns were raised in the population enrolled in the ESEMPiO database and treated in a real-life practice. Median progression-free survival and overall survival were 3.2 and 10.1 months, respectively. EM activity was similar between breast cancer subtypes.CONCLUSION: In metastatic breast cancer patients treated with EM in 'real-world' setting, the clinician-registered outcomes were comparable to those reported in pivotal trials. Furthermore, EM maintained clinical activity and a tolerable safety profile.

AB - AIM: We performed a multicenter retrospective cohort study of eribulin mesylate (EM) use in Italy, to describe the current practice for metastatic breast cancer patients (ESEMPiO) in the real-world.PATIENTS & METHODS: Baseline characteristics, treatment administration and safety were summarized using descriptive statistics.RESULTS: No safety concerns were raised in the population enrolled in the ESEMPiO database and treated in a real-life practice. Median progression-free survival and overall survival were 3.2 and 10.1 months, respectively. EM activity was similar between breast cancer subtypes.CONCLUSION: In metastatic breast cancer patients treated with EM in 'real-world' setting, the clinician-registered outcomes were comparable to those reported in pivotal trials. Furthermore, EM maintained clinical activity and a tolerable safety profile.

U2 - 10.2217/fon-2018-0324

DO - 10.2217/fon-2018-0324

M3 - Article

C2 - 30411979

JO - Future Oncology

JF - Future Oncology

SN - 1479-6694

ER -